Antistax® in Patients With Chronic Venous Insufficiency
Launched by BOEHRINGER INGELHEIM · Jul 15, 2014
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female
- • Between 25 and 75 years of age
- • CVI I or CVI II (without expanded trophic disturbances)
- • Willing and able to give written informed consent prior to participation in the study
- Exclusion Criteria:
- Concomitant disease(s) exclusion criteria:
- • Decompensated cardiac insufficiency
- • Edema not due to venous disease of the legs (e.g. latent cardiac insufficiency, renal insufficiency, lymph edema, etc)
- • Peripheral arterial disease (ankle/arm pressure index \< 0.9)
- • Current acute phlebitis or thrombosis
- • Renal insufficiency (Serum creatinine \> 1.5 mg/dl)
- • Liver disease (SGPT (ALAT) \> 3x upper limit of normal)
- • Other diseases: insulin-dependent diabetes mellitus, neuropathies, hyper- or hypocalcaemia, malignancies
- • Anamnestic indications of diabetic microangiopathy or polyneuropathy
- • Drug and/or alcohol abuse
- • Severe climacteric complaints
- • Immobility
- • Avalvulia
- • Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
- • State after pulmonary embolism
- • Recognized hypersensitivity to the trial drug ingredients
- • Current florid venous ulcus
- • Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compressive treatment, phlebectomy, etc.
- Previous treatment(s) exclusion criteria:
- • Treatment with venous drugs within the last 4 weeks
- • Treatment with laxatives which affect fluid or electrolyte balance within the last 8 days
- • Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors or calcium antagonists within the last 8 days
- • Changes in post-menopausal Hormone replacement within the last 2 months
- Concomitant treatment/non-drug therapy exclusion criteria:
- • Other venous drugs apart from the trial medication
- • Compression therapy
- • Venous surgery at the leg(s)
- • Extensive use (on more than a total of 6 days during the entire trial) of laxatives which affect fluid or electrolyte balance
- • Major surgery requiring full anesthesia
- Other exclusion criteria:
- • Previously studied under this protocol
- • Participation in another clinical trial within the previous 90 days or during the present study
- • Patients who have visited a sauna or had other thermal applications in the previous day before any visit
- • Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
- • Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
- • Patients in a bad general health state according to the investigator's judgment
About Boehringer Ingelheim
Boehringer Ingelheim is a global, research-driven pharmaceutical company dedicated to improving health and quality of life through innovative therapies. Established in 1885 and headquartered in Ingelheim, Germany, the company focuses on the development of prescription medicines in key therapeutic areas, including respiratory diseases, cardiovascular health, oncology, and immunology. Boehringer Ingelheim is committed to advancing medical science through rigorous clinical trials and collaborative research, striving to bring novel treatments to patients while upholding the highest standards of safety and efficacy. With a strong emphasis on sustainability and corporate responsibility, the company aims to make a meaningful impact on global health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials